已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

First-line atezolizumab monotherapy versus single-agent chemotherapy in patients with non-small-cell lung cancer ineligible for treatment with a platinum-containing regimen (IPSOS): a phase 3, global, multicentre, open-label, randomised controlled study

阿替唑单抗 医学 内科学 养生 人口 化疗方案 化疗 长春瑞滨 肿瘤科 临床终点 性能状态 肺癌 吉西他滨 临床研究阶段 外科 癌症 临床试验 彭布罗利珠单抗 免疫疗法 顺铂 环境卫生
作者
Siow Ming Lee,Christian Schulz,Kumar Prabhash,Dariusz M. Kowalski,Aleksandra Szczęsna,Baohui Han,Achim Rittmeyer,Toby Talbot,David Vicente,Raffaele Califano,Diego Cortinovis,Anh T. Le,Dingzhi Huang,Geoffrey Liu,Federico Cappuzzo,Jessica Reyes Contreras,Martin Reck,Ramón Palmero,Milena Perez Mak,Youyou Hu
出处
期刊:The Lancet [Elsevier BV]
卷期号:402 (10400): 451-463 被引量:92
标识
DOI:10.1016/s0140-6736(23)00774-2
摘要

Background Despite immunotherapy advancements for patients with advanced or metastatic non-small-cell lung cancer (NSCLC), pivotal first-line trials were limited to patients with an Eastern Cooperative Oncology Group performance status (ECOG PS) 0–1 and a median age of 65 years or younger. We aimed to compare the efficacy and safety of first-line atezolizumab monotherapy with single-agent chemotherapy in patients ineligible for platinum-based chemotherapy. Methods This trial was a phase 3, open-label, randomised controlled study conducted at 91 sites in 23 countries across Asia, Europe, North America, and South America. Eligible patients had stage IIIB or IV NSCLC in whom platinum-doublet chemotherapy was deemed unsuitable by the investigator due to an ECOG PS 2 or 3, or alternatively, being 70 years or older with an ECOG PS 0–1 with substantial comorbidities or contraindications for platinum-doublet chemotherapy. Patients were randomised 2:1 by permuted-block randomisation (block size of six) to receive 1200 mg of atezolizumab given intravenously every 3 weeks or single-agent chemotherapy (vinorelbine [oral or intravenous] or gemcitabine [intravenous]; dosing per local label) at 3-weekly or 4-weekly cycles. The primary endpoint was overall survival assessed in the intention-to-treat population. Safety analyses were conducted in the safety-evaluable population, which included all randomised patients who received any amount of atezolizumab or chemotherapy. This trial is registered with ClinicalTrials.gov, NCT03191786. Findings Between Sept 11, 2017, and Sept 23, 2019, 453 patients were enrolled and randomised to receive atezolizumab (n=302) or chemotherapy (n=151). Atezolizumab improved overall survival compared with chemotherapy (median overall survival 10·3 months [95% CI 9·4–11·9] vs 9·2 months [5·9–11·2]; stratified hazard ratio 0·78 [0·63–0·97], p=0·028), with a 2-year survival rate of 24% (95% CI 19·3–29·4) with atezolizumab compared with 12% (6·7–18·0) with chemotherapy. Compared with chemotherapy, atezolizumab was associated with stabilisation or improvement of patient-reported health-related quality-of-life functioning scales and symptoms and fewer grade 3–4 treatment-related adverse events (49 [16%] of 300 vs 49 [33%] of 147) and treatment-related deaths (three [1%] vs four [3%]). Interpretation First-line treatment with atezolizumab monotherapy was associated with improved overall survival, a doubling of the 2-year survival rate, maintenance of quality of life, and a favourable safety profile compared with single-agent chemotherapy. These data support atezolizumab monotherapy as a potential first-line treatment option for patients with advanced NSCLC who are ineligible for platinum-based chemotherapy. Funding F Hoffmann-La Roche and Genentech Inc, a member of the Roche group.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
Foxjker完成签到 ,获得积分10
1秒前
YDX完成签到,获得积分20
2秒前
4秒前
CartGo完成签到,获得积分10
7秒前
脑洞疼应助十二采纳,获得10
7秒前
kenti2023完成签到 ,获得积分10
8秒前
Meyako完成签到 ,获得积分10
8秒前
CHEN发布了新的文献求助10
10秒前
amber完成签到 ,获得积分10
10秒前
自信的网络完成签到 ,获得积分10
12秒前
马马完成签到 ,获得积分10
13秒前
Aurora发布了新的文献求助10
15秒前
万能图书馆应助纯真衬衫采纳,获得10
16秒前
马马完成签到 ,获得积分10
19秒前
21秒前
MCRing完成签到,获得积分10
21秒前
小L完成签到 ,获得积分10
22秒前
环走鱼尾纹完成签到 ,获得积分10
22秒前
文子完成签到 ,获得积分10
23秒前
量子星尘发布了新的文献求助10
25秒前
派大星发布了新的文献求助10
25秒前
可爱的函函应助Aurora采纳,获得10
26秒前
krajicek发布了新的文献求助10
26秒前
所所应助可耐的青雪采纳,获得10
30秒前
CHEN完成签到,获得积分20
30秒前
czy完成签到 ,获得积分10
30秒前
31秒前
深情安青应助梦想里采纳,获得10
32秒前
水若琳完成签到 ,获得积分10
34秒前
合适的台灯完成签到,获得积分10
35秒前
派大星完成签到 ,获得积分20
36秒前
小蘑菇应助CHEN采纳,获得10
38秒前
蘇q完成签到 ,获得积分10
38秒前
可爱的函函应助宁紫涵采纳,获得10
38秒前
经钧发布了新的文献求助30
40秒前
zpj完成签到 ,获得积分10
41秒前
梦想里完成签到,获得积分10
42秒前
44秒前
mauve完成签到 ,获得积分10
45秒前
酷波er应助科研通管家采纳,获得10
47秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 700
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3976583
求助须知:如何正确求助?哪些是违规求助? 3520659
关于积分的说明 11204399
捐赠科研通 3257298
什么是DOI,文献DOI怎么找? 1798683
邀请新用户注册赠送积分活动 877842
科研通“疑难数据库(出版商)”最低求助积分说明 806595